An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
NCT07224373
This study is recruiting at 6 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Multiple Sclerosis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- August 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
District of Columbia · 1
- Research Site · Washington D.C., DC
Missouri · 1
- Research Site · St Louis, MO
New York · 2
- Research Site · New York, NY
- Research Site · New York, NY
Washington · 1
- Research Site · Seattle, WA
Wisconsin · 1
- Research Site · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.